Press

Numinus Wellness Charts Path To Profitability While Strengthening Community Ties

May 30 • 4 min read

Vancouver, British Columbia–(Newsfile Corp. – May 30, 2024) – Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) (“Numinus” or the “Company”), a leader in mental health care and in advancing evidence-based psychedelic-assisted therapies, announces a strategic blueprint aimed at fortifying its footprint across the United States. Through a comprehensive cost optimization initiative, Numinus is poised to strengthen its already established…

Patient dosing commenced in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea

May 30 • 6 min read

NEW YORK and MELBOURNE, Australia, May 30, 2024 (GLOBE NEWSWIRE) — Incannex Healthcare Inc. (Nasdaq: IXHL), (‘Incannex’ or the ‘Company’), a pharmaceutical company developing unique medicinal cannabinoid pharmacotherapies and psychedelic medicine therapies is pleased to announce that patient dosing has commenced in the Company’s Phase 2/3 clinical trial to assess safety and efficacy of IHL-42X in…

Former Merck Director and Vanderbilt Vice-Chancellor, Dr. Harry Jacobson, to Join Lobe Sciences Board of Directors

May 30 • 3 min read

VANCOUVER, British Columbia, May 30, 2024–(BUSINESS WIRE)–Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) (“Lobe” or the “Company”), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases today announced that Dr. Harry Jacobson has agreed to join its Board of Directors in the coming months. Dr. Jacobson brings over three decades of distinguished…

Numinus Wellness Receives Health Canada Approval for Study into Group Model for MDMA-Assisted Therapy

May 30 • 3 min read

VANCOUVER, BC, May 30, 2024 /CNW/ – Numinus Wellness Inc. (“Numinus” or the “Company“) (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing traditional and innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, announces that Health Canada has approved the Company’s Clinical Trial Application to examine the feasibility of a group model in MDMA-assisted psychotherapy enrolling…

Red Light Holland Initiates Psilocybin Extraction Phase with PharmAla Following Successful Testing and Preparation by CCrest Labs

May 29 • 3 min read

Toronto, Ontario–(Newsfile Corp. – May 27, 2024) – Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) (“Red Light Holland”), a company engaged in the production, growth, and sale of functional mushrooms and mushroom home grow kits in North America and Europe, as well as a premium brand of psilocybin truffles to the legal,…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435